ClinicalTrials.gg
CompletedNCT00369382Updated May 30, 2011Results posted

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

A Phase 4 interventional study of cyclosporine or tacrolimus and sirolimus in Graft Rejection and Kidney Failure, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer. Completed at 23 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-05-30.

Sponsored by Wyeth is now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
121
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies testing sirolimus in Renal Insufficiency — none open to participants now, none under way, none of them phase 3. Sirolimus · Renal Insufficiency.

Enrollment
4th of 16
121 · median 63
Started
2006
with 2 others
Phase 4
6 of 16
none open now
Registered
12th of 16
by date
Lead sponsor
7 of 16
Wyeth is now a wholly owned subsidiary of Pfizer

Among the 16 studies testing sirolimus in Renal Insufficiency, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 6 in phase 4, and was the 12th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

None of the 16 studies testing sirolimus in Renal Insufficiency is open now. The open studies under Renal Insufficiency, anywhere →

About sirolimus

Sirolimus: first FDA approval 1999 (RAPAMUNE), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies testing sirolimus in Renal Insufficiency as a file.
02

Study summary

The primary purpose of this study is to determine whether converting from calcineurin inhibitor (CNI) therapy to sirolimus therapy will be more effective than continuing calcineurin inhibitor therapy with respect to renal function in cardiac transplant recipients with mild to moderate renal dysfunction.

03

Conditions studied

  • Graft Rejection
  • Kidney Failure

Browse trials for

Keywords

  • Heart Transplant
  • Kidney Failure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant.
  • 12 months after cardiac transplantation but less than 96 months post-transplantation.

Exclusion criteria

Exclusion Criteria:

  • Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients).
  • Prior or current use of sirolimus or everolimus unless administration was part of a "CNI holiday" lasting no more than 10 days.
  • History of acute rejection within the last 3 months, within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and (HIV) patients.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
121 participants (actual)

Study arms

  • Active comparator
    1

    Group 1: Continuation of CNI regimen

    Drug: cyclosporine or tacrolimus

  • Experimental
    2

    Group 2: (CNI-Free) Conversion to SRL-based regimen

    Drug: sirolimus

Interventions

  • Drugcyclosporine or tacrolimus

    Drug pages: Cyclosporine · Tacrolimus

    Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.

    Also known as: Brand names for cyclosporine are Neoral®, Sandimmune®, and Gengraf®; brand names for tacrolimus are Prograf® and Adagraf™.

  • Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.

    Also known as: Rapamune®

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization

    Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m\^2). Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.

    Time frame: Baseline and Week 52

  2. Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline

    Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.

    Time frame: Baseline

Secondary outcomes

  1. Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization

    Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.

    Time frame: Baseline and Weeks 4, 16, 24, 32, and 40

  2. Change From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization

    Creatinine clearance calculated using MDRD equation. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function. Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center.

    Time frame: Baseline and Weeks 4, 16, 24, 32, 40 and 52

  3. Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline

    Creatinine clearance calculated using MDRD equation. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.

    Time frame: Baseline

  4. Change From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization

    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent. Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function. Least squares mean adjusted for treatment group and center.

    Time frame: Baseline and Weeks 4, 16, 24, 32, 40, and 52

  5. Serum Creatinine Level at Baseline

    Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.

    Time frame: Baseline

  6. Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)

    The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable. Time points calculated as study days, relative to time of randomization of study medication. Observed data multiplied by a scale factor of 365 to express an annual change.

    Time frame: Baseline to discontinuation (up to Week 52)

  7. Overall Survival (OS)

    Survival time from the start of study treatment to date of death due to any cause, censored at the last visit if no death. Death was determined from the Death report. The distribution of time to death was to be estimated using Kaplan-Meier method and compared between treatment groups with a proportional hazard model. The number and percent of survival at 6 and 12 months were to be reported.

    Time frame: Baseline until death (up to Week 56)

  8. Number of Participants With Acute Rejection

    Based on International Society for Heart and Lung Transplantation \[ISHLT\] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment. Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated.

    Time frame: Baseline to Week 52

  9. Number of Participants With Biopsy-confirmed Acute Rejection by Severity

    Severity of acute rejection summarized using revised 2005 ISHLT criteria. Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis.

    Time frame: Baseline to Week 52

  10. Time to First Acute Rejection

    Time from baseline to first biopsy-confirmed acute rejection defined as any of the following (based on ISHLT 1990 criteria): all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.

    Time frame: Baseline to Week 52

  11. Number of Participants Requiring Antibody Use in Treatment of Acute Rejection

    Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise. Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.

    Time frame: Baseline to Week 52

  12. Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy

    Time frame: Baseline up to Week 52

07

Results

Posted May 23, 2011

Participant flow

Actual number of participants randomized was 121; however 5 participants randomized in error. They were withdrawn from study as screen failures, not administered study drug. Participants randomized (121) lower than planned (200); more sites added, time period to enroll extended twice up to 2.5 years. Despite this, final enrollment below planned.

Participant flow — Overall Study
MilestoneCyclosporine or TacrolimusSirolimus (SRL)
Started5957
Received treatment5757
Completed assigned treatment regimen4833
Completed4954
Not completed103
Withdrew: Death02
Withdrew: Physician decision21
Withdrew: Withdrawal by subject50
Withdrew: Randomized, not treated20
Withdrew: Other10

Outcome measures

PrimaryChange From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization

Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is greater than or equal to (≥) 90 milliliters per minute per 1.73 meters squared (mL/min/1.73m\^2). Change from baseline=CC at Week 52 minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.

Time frame:
Baseline and Week 52
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 52 Weeks Post-randomization-1.35 ± 1.183.03 ± 1.29
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.004 (two-sided alpha = 0.05)Analysis of covariance (ANCOVA) with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
PrimaryCalculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline

Creatinine clearance at baseline calculated using Cockcroft-Gault equation and adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.

Time frame:
Baseline
Reported as:
Mean · mL/min/1.73m^2
Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Calculated Creatinine Clearance (Cockcroft-Gault Equation) at Baseline57.09 ± 11.9657.75 ± 14.04
SecondaryChange From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization

Creatinine Clearance (CC) calculated using Cockcroft-Gault equation, adjusted for body surface area. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function; Least squares mean adjusted for baseline calculated creatinine clearance and center.

Time frame:
Baseline and Weeks 4, 16, 24, 32, and 40
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline in Calculated Creatinine Clearance (Cockcroft-Gault Equation) at 4, 16, 24, 32, and 40 Weeks Post-randomization
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Week 4-0.20 ± 1.062.96 ± 1.16
Week 16-2.16 ± 1.373.79 ± 1.50
Week 24-1.91 ± 1.282.15 ± 1.40
Week 32-0.76 ± 1.322.22 ± 1.45
Week 400.34 ± 1.392.70 ± 1.52
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.018 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = <.001 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.012 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.072 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.175 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (Cockcroft-Gault) as a covariate and treatment group and center as factors
SecondaryChange From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization

Creatinine clearance calculated using MDRD equation. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2. Change from baseline=CC at Week X minus CC at baseline where higher scores represented improved renal function. Least squares mean adjusted for baseline calculated creatinine clearance (MDRD) and center.

Time frame:
Baseline and Weeks 4, 16, 24, 32, 40 and 52
Reported as:
Least squares mean · mL/min/1.73m^2
Change From Baseline in Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at 4, 16, 24, 32, 40 and 52 Weeks Post-randomization
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Week 4-0.00 ± 1.163.18 ± 1.25
Week 16-1.92 ± 1.404.30 ± 1.51
Week 24-1.47 ± 1.362.54 ± 1.47
Week 32-0.15 ± 1.432.44 ± 1.54
Week 400.69 ± 1.522.69 ± 1.64
Week 52-0.90 ± 1.263.26 ± 1.36
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.031 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = <0.001 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.020 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.151 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.295 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.010 (alpha is unadjusted)ANCOVA with baseline creatinine clearance (MDRD) as a covariate and treatment group and center as factors
SecondaryCalculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline

Creatinine clearance calculated using MDRD equation. Calculated CC: method to approximate kidney function. It measures rate creatinine (substance formed from metabolism of creatine) is cleared from blood by kidneys. Normal adult creatinine clearance is ≥ 90 mL/min/1.73m\^2.

Time frame:
Baseline
Reported as:
Mean · mL/min/1.73m^2
Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Calculated Creatinine Clearance (Modification of Diet in Renal Disease [MDRD] Equation) at Baseline55.39 ± 12.8454.47 ± 14.14
SecondaryChange From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine. Normal adult blood levels of creatinine=45 to 90 micromoles per liter (mcmol/L) for females, 60 to 110 mcmol/L for males, however normal values are age-dependent. Change from baseline=creatinine level at Week x minus baseline level where higher scores represented decreased kidney function. Least squares mean adjusted for treatment group and center.

Time frame:
Baseline and Weeks 4, 16, 24, 32, 40, and 52
Reported as:
Least squares mean · mcmol/L
Change From Baseline in Serum Creatinine Level at 4, 16, 24, 32, 40, and 52 Weeks Post-randomization
mcmol/LCyclosporine or TacrolimusSirolimus (SRL)
Week 41.68 ± 2.00-4.95 ± 2.15
Week 167.96 ± 2.62-5.52 ± 2.82
Week 248.02 ± 2.21-0.89 ± 2.37
Week 324.08 ± 2.52-2.80 ± 2.71
Week 402.44 ± 2.702.81 ± 2.90
Week 524.76 ± 2.22-4.39 ± 2.39
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.009 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = <0.001 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.002 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.030 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.121 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · ANCOVA · p = 0.001 (alpha is unadjusted)ANCOVA with baseline serum creatinine as a covariate and treatment group and center as factors
SecondarySerum Creatinine Level at Baseline

Serum creatinine is an indicator of kidney function. Creatinine is a substance formed from the metabolism of creatine, commonly found in blood, urine, and muscle tissue. It is removed from the blood by the kidneys and excreted in urine.

Time frame:
Baseline
Reported as:
Mean · mcmol/L
Serum Creatinine Level at Baseline
mcmol/LCyclosporine or TacrolimusSirolimus (SRL)
Serum Creatinine Level at Baseline125.42 ± 23.15126.21 ± 29.63
SecondaryAnnual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)

The change in creatinine clearance over time assessed using the random coefficient slope of the regression line with creatinine clearance as the dependent variable and study day as the independent variable. Time points calculated as study days, relative to time of randomization of study medication. Observed data multiplied by a scale factor of 365 to express an annual change.

Time frame:
Baseline to discontinuation (up to Week 52)
Reported as:
Number · mL/min/1.73m^2
Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)
mL/min/1.73m^2Cyclosporine or TacrolimusSirolimus (SRL)
Annual Change in Calculated Creatinine Clearance (Cockcroft-Gault Equation)-0.740 (-2.921 to 1.441)1.571 (-0.447 to 3.588)
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · Random coefficient model · p = 0.126 (alpha is unadjusted) · Slope difference (cni - srl): -2.311 · 95% CI -5.282 to 0.660Random coefficient model with each participant's creatinine clearance function of time on treatment; intra-subject regression coefficients considered random.
SecondaryOverall Survival (OS)

Survival time from the start of study treatment to date of death due to any cause, censored at the last visit if no death. Death was determined from the Death report. The distribution of time to death was to be estimated using Kaplan-Meier method and compared between treatment groups with a proportional hazard model. The number and percent of survival at 6 and 12 months were to be reported.

Time frame:
Baseline until death (up to Week 56)
Reported as:
Number · Weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants With Acute Rejection

Based on International Society for Heart and Lung Transplantation \[ISHLT\] 1990 criteria: rejections Grade 3A or higher, rejection accompanied by hemodynamic compromise or requiring treatment. Grade 3A or higher included: multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis. Biopsies performed for clinically suspected rejection (for cause), site's standard of care (site protocol biopsy), or protocol mandated.

Time frame:
Baseline to Week 52
Reported as:
Number · Participants
Number of Participants With Acute Rejection
ParticipantsCyclosporine or TacrolimusSirolimus (SRL)
For cause biopsies (n=57, 57)15
Standard of Care biopsies (n=11, 11)02
Protocol mandated biopsies (n=0, 39)NA7
Statistical analysis
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · Fisher Exact · p = 0.206 (alpha is unadjusted)
  • Cyclosporine or Tacrolimus vs Sirolimus (SRL) · Fisher Exact · p = 0.476 (alpha is unadjusted)
SecondaryNumber of Participants With Biopsy-confirmed Acute Rejection by Severity

Severity of acute rejection summarized using revised 2005 ISHLT criteria. Grade 0R: no rejection, Grade 1R: Focal (perivascular or interstitial) infiltrate without necrosis, diffuse but sparse infiltrate without necrosis, or one focus only with aggressive infiltration and/or focal myocyte damage, Grade 2R:Multifocal aggressive infiltrates and/or myocyte damage, and Grade 3R:Diffuse inflammatory process with necrosis, or diffuse aggressive polymorphous with necrosis, increased infiltrate, changes in edema, hemorrhage and vasculitis.

Time frame:
Baseline to Week 52
Reported as:
Number · Participants
Number of Participants With Biopsy-confirmed Acute Rejection by Severity
ParticipantsCyclosporine or TacrolimusSirolimus (SRL)
Grade 0R protocol mandatedNA0
Grade 0R for cause00
Grade 0R site protocol00
Grade 1R protocol mandatedNA0
Grade 1R for cause00
Grade 1R site protocol00
Grade 2R protocol mandatedNA6
Grade 2R for cause04
Grade 2R site protocol01
Grade 3R protocol mandatedNA1
Grade 3R for cause11
Grade 3R site protocol01
SecondaryTime to First Acute Rejection

Time from baseline to first biopsy-confirmed acute rejection defined as any of the following (based on ISHLT 1990 criteria): all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.

Time frame:
Baseline to Week 52
Reported as:
Number · Weeks

No measurements were reported for this outcome.

SecondaryNumber of Participants Requiring Antibody Use in Treatment of Acute Rejection

Number of participants requiring antilymphocyte antibody therapy with suspected or biopsy-proven, steroid-resistant, acute rejection with or without hemodynamic compromise. Acute rejection based on ISHLT 1990 criteria: all rejections Grade 3A or higher, any rejection accompanied by hemodynamic compromise, or any rejection requiring treatment. ISHLT Grade 3A or higher included: Multifocal aggressive infiltrates and/or myocyte damage, diffuse inflammatory process with necrosis, diffuse aggressive polymorphus with necrosis, increased infiltrates, and changes in edema, hemorrhage, or vasculitis.

Time frame:
Baseline to Week 52
Reported as:
Number · Participants
Number of Participants Requiring Antibody Use in Treatment of Acute Rejection
ParticipantsCyclosporine or TacrolimusSirolimus (SRL)
Number of Participants Requiring Antibody Use in Treatment of Acute Rejection10
SecondaryNumber of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy
Time frame:
Baseline up to Week 52
Reported as:
Number · Participants
Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy
ParticipantsSirolimus (SRL)
Number of Participants in Sirolimus Treatment Group Requiring Conversion Back to CNI Therapy21

Adverse events

Collected over Baseline up to Week 56. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cyclosporine or Tacrolimus—13/57 (22.8%)40/57 (70.2%)
Sirolimus (SRL)—30/57 (52.6%)54/57 (94.7%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventCyclosporine or TacrolimusSirolimus (SRL)
Transplant rejectionGeneral disorders1/5713/57
PneumoniaRespiratory, thoracic and mediastinal disorders0/574/57
MyalgiaMusculoskeletal and connective tissue disorders0/573/57
Skin carcinomaSkin and subcutaneous tissue disorders3/572/57
CholelithiasisGastrointestinal disorders2/570/57
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders1/572/57
Abdominal painGeneral disorders1/571/57
AstheniaGeneral disorders0/571/57
FeverGeneral disorders0/571/57
Lab test abnormalGeneral disorders1/570/57
Most frequent other events
Showing 10 of 53
Most frequent other events
EventCyclosporine or TacrolimusSirolimus (SRL)
Peripheral edemaMetabolism and nutrition disorders9/5718/57
RashSkin and subcutaneous tissue disorders2/5716/57
DiarrheaGastrointestinal disorders6/5715/57
Uterine fibroids enlargedRenal and urinary disorders1/50/12
Uterine hemorrhageRenal and urinary disorders1/50/12
Upper respiratory infectionRespiratory, thoracic and mediastinal disorders11/5710/57
HeadacheGeneral disorders2/578/57
Aphthous stomatitisGastrointestinal disorders0/578/57
AcneSkin and subcutaneous tissue disorders0/578/57
Abdominal painGeneral disorders3/577/57

Baseline characteristics

Age Continuous
Age Continuous(years)Cyclosporine or TacrolimusSirolimus (SRL)Total
Mean58.93 ± 8.0157.40 ± 9.4258.18 ± 8.73
Sex: Female, Male
Sex: Female, Male(Participants)Cyclosporine or TacrolimusSirolimus (SRL)Total
Female51217
Male544599
08

Study locations

23 sites
  • Pfizer Investigational Site
    Tampa, Florida 33606, United States
  • Pfizer Investigational Site
    Rochester, Minnesota 55905, United States
  • Pfizer Investigational Site
    New York, New York 10027-6902, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • Pfizer Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Pfizer Investigational Site
    Pittsburgh, Pennsylvania 15213, United States
  • Pfizer Investigational Site
    Houston, Texas 77030, United States
  • Pfizer Investigational Site
    Norfolk, Virginia 23507, United States
  • Pfizer Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • Pfizer Investigational Site
    Vienna, A-1090, Austria
  • Pfizer Investigational Site
    Montreal, Quebec H1T 1C8, Canada
  • Pfizer Investigational Site
    Sainte-Foy, Quebec G1V 4G5, Canada
  • Pfizer Investigational Site
    Quebec, G1V 4G5, Canada
  • Pfizer Investigational Site
    Epsom, Auckland 1003, New Zealand
  • Pfizer Investigational Site
    Auckland, New Zealand
  • Pfizer Investigational Site
    L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Pfizer Investigational Site
    Santander, Cantabria 39008, Spain
  • Pfizer Investigational Site
    Barcelona, 08036, Spain
  • Pfizer Investigational Site
    La Coru?a, 15001, Spain
  • Pfizer Investigational Site
    Madrid, 28035, Spain
  • Pfizer Investigational Site
    Sevilla, 41013, Spain
  • Pfizer Investigational Site
    Valencia, 46009, Spain
  • Pfizer Investigational Site
    Bern, 3010, Switzerland
09

References and documents

Publications

  • Zuckermann A, Keogh A, Crespo-Leiro MG, Mancini D, Vilchez FG, Almenar L, Brozena S, Eisen H, Tai SS, Kushwaha S. Randomized controlled trial of sirolimus conversion in cardiac transplant recipients with renal insufficiency. Am J Transplant. 2012 Sep;12(9):2487-97. doi: 10.1111/j.1600-6143.2012.04131.x. Epub 2012 Jul 9. PubMed 22776430 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2006, a primary completion of Apr 2010 and a completion of May 2010. It does not say whether these dates are actual or estimated.

Results were first posted in May 2011, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2006
First posted
Aug 29, 2006
Start
Sep 2006
Primary completionActual
Apr 2010
CompletionActual
May 2010
Results first posted
May 23, 2011
Last update
May 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00369382
First posted
Aug 29, 2006
Start date
Sep 2006
Primary completion
Apr 2010
Completion
May 2010
Results posted
May 23, 2011
Last update
May 30, 2011

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sirolimus

Start the discussion